Vol 12 - Aug 2025 Evidence for Primary Care
Evidence for Primary Care: the latest evidence from the Trip Database
A summary of some of the most important new documents for primary care that have recently been added to the Trip Database
Hot Hearts, Hidden Bugs, and Tricky UTIs
This month’s evidence reminds us that medicine is never boring. First, the ESC sounds the alarm: heatwaves aren’t just sweaty nuisances, they’re cardiovascular risk factors. Dehydration, inflammation, and poor housing stack the odds against vulnerable patients—so hydration advice and medication reviews matter when the temperature soars.
Meanwhile, Helicobacter pylori makes its case as public enemy number one for the stomach. Eradication therapy doesn’t just ease dyspepsia, it prevents gastric cancer—rarely do antibiotics offer such a clear cancer-prevention win.
And finally, the IDSA brings order to the chaos of complicated UTIs. Their stepwise guidance is simple: start broad if your patient is septic, but don’t forget to de-escalate once cultures return. Stewardship and survival can go hand in hand.
From heat to helicobacter to hospital bugs—the common thread is early recognition and smart action.
In This Edition
- How do heat extremes affect cardiovascular health and what can be done to reduce the risks?
- Does Helicobacter pylori eradication therapy prevent gastric cancer in H. pylori-positive individuals?
- How should complicated urinary tract infections (cUTIs) be treated and managed according to the new IDSA guidelines?
- How can antidepressants be stopped safely while minimizing withdrawal problems?
- Does semaglutide improve cardiovascular and renal outcomes in people with type 2 diabetes regardless of prior cardiovascular disease or body mass index?
- What are the updated recommendations for diagnosing and managing adult sinusitis?
- Can a clinical decision support system improve diagnosis and treatment of opioid use disorder in primary care?
- What are the 2025 updated recommendations for pharmacotherapy in adult obesity management?
- Does a prescribed digital health app reduce migraine days compared with a control app?
- How effective and equitable is the NHS England low-calorie diet pilot for adults with type 2 diabetes?
- Does bedtime dosing of antihypertensive medication provide better nocturnal blood pressure control than morning dosing?
- What are the updated ECCO-ESGAR-ESP-IBUS recommendations for diagnosing and monitoring patients with inflammatory bowel disease?
- How should primary dysmenorrhea be investigated and treated?
- Can once-weekly insulin icodec replace daily long-acting insulin in type 2 diabetes?
European Society of Cardiology
How do heat extremes affect cardiovascular health and what can be done to reduce the risks?
Clinical Bottom Line: Heat extremes, including hot weather and heatwaves, increase the risk of cardiovascular morbidity and mortality, especially in older adults and people with pre-existing CVD. Mechanisms include increased inflammation, myocardial oxygen demand, and dehydration, compounded by social inequities such as inadequate housing and lack of cooling. Clinicians should recognize heat as a cardiovascular risk factor, identify vulnerable patients, and support preventive strategies (hydration, access to cooling, medication review during heatwaves).
Summary: This scientific statement from multiple ESC associations highlights the growing cardiovascular threat of heat extremes in the context of climate change. Epidemiological evidence shows clear links between elevated temperatures and adverse cardiovascular outcomes, yet physiological mechanisms remain incompletely understood. Heat exposure can trigger inflammation, strain the heart, and cause fluid imbalance, all of which elevate cardiovascular risk. Vulnerable populations—including the elderly, those with existing CVD, and individuals facing socioeconomic disadvantages—are disproportionately affected. The statement calls for further research into mechanisms, tailored interventions, and policies addressing social determinants of health to mitigate the cardiovascular burden of heat extremes.
View ArticleGastroenterology
Does Helicobacter pylori eradication therapy prevent gastric cancer in H. pylori-positive individuals?
Clinical Bottom Line: Eradication therapy for Helicobacter pylori significantly reduces the risk of developing gastric cancer and lowers gastric cancer–related mortality in H. pylori-positive individuals, both in those without neoplasia and in those undergoing endoscopic mucosal resection (EMR). Evidence from randomized controlled trials and observational studies is consistent, supporting the role of H. pylori eradication as an effective cancer prevention strategy.
Summary: This updated systematic review and meta-analysis included 11 RCTs and 13 observational studies evaluating the impact of H. pylori eradication therapy on gastric cancer outcomes. In RCTs, eradication therapy reduced the risk of gastric cancer in healthy H. pylori-positive adults (RR 0.64, 95% CI 0.48–0.84) and in patients with gastric neoplasia post-EMR (RR 0.52, 95% CI 0.38–0.71). It also lowered gastric cancer mortality (RR 0.78, 95% CI 0.62–0.98). Observational studies showed similar reductions in gastric cancer incidence, reinforcing the consistency of the evidence. Overall, the findings support population-level and high-risk group H. pylori eradication as a key preventive intervention against gastric cancer.
View ArticleInfectious Diseases Society of America
How should complicated urinary tract infections (cUTIs) be treated and managed according to the new IDSA guidelines?
Clinical Bottom Line: The 2025 IDSA guidelines recommend a stepwise approach to cUTI management: assess illness severity, resistance risk, patient factors, and local antibiograms. Broad-spectrum agents (3rd/4th gen cephalosporins, carbapenems, piperacillin-tazobactam, fluoroquinolones) are preferred for septic patients, while narrower choices are advised for non-septic patients. Switch to oral therapy and tailor duration once cultures are available.
Summary: These first IDSA guidelines on cUTI update definitions, provide empiric antibiotic recommendations, and stress balancing early effective treatment with antimicrobial stewardship. Key points include using broad coverage in sepsis, narrower options in stable patients, and a structured four-step decision process to guide therapy until cultures allow de-escalation.
View ArticleTherapeutics Letter
How can antidepressants be stopped safely while minimizing withdrawal problems?
Clinical Bottom Line: Antidepressant withdrawal is common, affecting about half of those who stop treatment. Symptoms can range from insomnia and mood changes to severe effects like “brain zaps” or akathisia. Gradual tapering—sometimes over months or years—under medical supervision reduces withdrawal risk and improves patient outcomes.
Summary: This Therapeutics Letter highlights the risks of stopping antidepressants abruptly and stresses the importance of slow, supported tapering. Withdrawal symptoms are frequent and can be distressing, especially after long-term or high-dose use. Safe discontinuation involves shared decision-making, careful dose reductions (sometimes in very small steps), regular follow-up, and the option to pause or reverse tapering if needed. With planning and support, most patients can discontinue antidepressants safely and successfully.
View ArticleDiabetes Obes Metab.
Does semaglutide improve cardiovascular and renal outcomes in people with type 2 diabetes regardless of prior cardiovascular disease or body mass index?
Clinical Bottom Line: In people with type 2 diabetes at high cardiovascular risk, semaglutide reduces major adverse cardiovascular events and the risk of nephropathy compared with placebo. Benefits were consistent regardless of prior cardiovascular disease or baseline BMI and were not explained solely by weight loss.
Summary: This pooled post hoc analysis of SUSTAIN 6 and PIONEER 6 examined semaglutide’s effects on cardiorenal outcomes in people with type 2 diabetes. Semaglutide lowered the risk of major adverse cardiovascular events and expanded outcomes (including heart failure and unstable angina) versus placebo, with trends toward reduced cardiovascular and all-cause death. It also significantly reduced the risk of new or worsening nephropathy. Importantly, effects were consistent across subgroups defined by prior cardiovascular disease and baseline BMI, and they persisted after adjusting for weight changes. These findings support semaglutide’s broad, direct cardiorenal protective effects in diverse T2D populations.
View ArticleAmerican Academy of Otolaryngology
What are the updated recommendations for diagnosing and managing adult sinusitis?
Clinical Bottom Line: The 2025 AAO-HNSF update on adult sinusitis emphasizes accurate diagnosis, reduced unnecessary imaging, and judicious antibiotic use. Watchful waiting (without antibiotics) is now recommended for all uncomplicated acute bacterial rhinosinusitis (ABRS), regardless of severity, with amoxicillin ± clavulanate as first-line therapy when antibiotics are needed. For chronic rhinosinusitis (CRS), clinicians should confirm inflammation objectively, use saline and intranasal corticosteroids, avoid routine antifungals or empiric antibiotics, and reserve biologics for selected patients with polyps.
Summary: This guideline update, replacing the 2015 version, incorporates new evidence from 194 systematic reviews and 133 RCTs. Key changes include broader use of watchful waiting for ABRS, updated antibiotic recommendations, and guidance on CRS management with attention to modifying conditions (e.g., asthma, cystic fibrosis, AERD). It discourages unnecessary imaging and antibiotics, expands the role of patient education, and introduces new recommendations on biologics. The update aims to improve diagnostic accuracy, reduce variation in care, and enhance outcomes while supporting antimicrobial stewardship.
View ArticleJAMA Intern Med.
Can a clinical decision support system improve diagnosis and treatment of opioid use disorder in primary care?
Clinical Bottom Line: An EHR-integrated clinical decision support system (CDSS) for opioid use disorder (OUD) in primary care increased naloxone prescribing and initiation of medications for OUD (MOUD) or specialty referrals. However, it did not increase overall OUD diagnoses, MOUD treatment duration, or reduce overdose and death rates.
Summary: This cluster randomized clinical trial included nearly 11,000 high-risk patients across primary care clinics in 4 US states. Use of an OUD-specific CDSS led to higher rates of naloxone prescriptions (OR 1.76) and MOUD initiation/referrals (OR 1.48) within 30 days of the index visit compared to usual care. However, there was no significant effect on new OUD diagnoses, sustained MOUD coverage at 90 days, or on overdose and mortality outcomes. These findings suggest CDSS tools can improve early treatment actions in primary care but alone are insufficient to improve longer-term outcomes.
View ArticleCMAJ
What are the 2025 updated recommendations for pharmacotherapy in adult obesity management?
Clinical Bottom Line: The 2025 Canadian guideline update reinforces pharmacotherapy as a core component of adult obesity management, alongside behavioural and surgical options. Medications such as GLP-1 receptor agonists, dual GIP–GLP-1 agonists, and setmelanotide should be considered for long-term use to support sustained weight loss and improve obesity-related complications. Therapy should be individualized, patient-centred, and combined with lifestyle changes, while compounded or unapproved drugs are not recommended.
Summary: This update builds on the 2020 and 2022 Canadian guidelines, incorporating new evidence through mid-2025, including the approval of tirzepatide and setmelanotide. It recommends using pharmacotherapy guided by BMI, central adiposity, and weight-related complications, with tailoring for comorbidities such as cardiovascular disease, type 2 diabetes, sleep apnea, NAFLD/MASH, and osteoarthritis. Pharmacotherapy is advised as part of long-term, comprehensive care, in conjunction with behavioural interventions and shared decision-making. The guideline also emphasizes reducing weight stigma and cautions against the use of compounded or unapproved medications.
View ArticleJAMA Netw Open.
Does a prescribed digital health app reduce migraine days compared with a control app?
Clinical Bottom Line: A prescribable digital migraine app (M-sense Migräne) was not superior to a control app with only headache diary functions in reducing monthly migraine days after 12 weeks. Both groups experienced similar improvements, suggesting benefits may come mainly from structured self-monitoring rather than additional app features.
Summary: In this randomized clinical trial of 476 adults with migraine, use of a prescribable digital health app was compared to a control app limited to diary features. After 12 weeks, migraine days decreased in both groups (to ~5–6 days/month), with no significant between-group difference (0.38 days; 95% CI, –0.32 to 1.08; P = .29). Secondary outcomes, including quality of life and self-efficacy, also showed no group differences. No serious adverse events occurred. The study highlights the importance of rigorous clinical trials in digital therapeutics, showing that headache diary use alone may provide meaningful benefit without added complexity.
View ArticleNIHR
How effective and equitable is the NHS England low-calorie diet pilot for adults with type 2 diabetes?
Clinical Bottom Line: The NHS low-calorie diet pilot achieved meaningful weight loss (mean 10.3 kg) and diabetes remission in about one-third of participants who completed the programme. It shows promise as a clinically effective and potentially cost-effective intervention, but challenges remain with referral equity, programme completion, and consistency of delivery.
Summary: This coproduced mixed-method evaluation examined the NHS England low-calorie diet pilot, combining qualitative data from service users, staff, and providers with clinical outcomes from over 7,500 participants. More than half of starters completed the programme, with substantial weight loss and remission of type 2 diabetes in 32% of those assessed. Barriers included inequalities in referrals, variable fidelity of delivery, and cultural and psychological support gaps, while enablers included strong cross-stakeholder collaboration. Cost-effectiveness analyses suggest potential benefits but no immediate cost savings. The evaluation has already informed improvements in equity, person-centred care, and delivery as the programme rolls out nationally, with long-term monitoring needed to confirm sustained effectiveness and impact.
View ArticleJAMA Netw Open.
Does bedtime dosing of antihypertensive medication provide better nocturnal blood pressure control than morning dosing?
Clinical Bottom Line: In patients with hypertension, bedtime dosing of olmesartan–amlodipine lowered nighttime systolic and diastolic blood pressure more effectively than morning dosing, improved circadian rhythm patterns, and did not increase nocturnal hypotension. Daytime and 24-hour blood pressure control were similar between groups.
Summary: The OMAN randomized clinical trial enrolled 720 untreated or recently untreated patients with hypertension across 15 Chinese hospitals. After 12 weeks, bedtime dosing reduced nighttime systolic BP by an additional 3 mm Hg and diastolic BP by 1.4 mm Hg compared with morning dosing, with more patients achieving target nocturnal control (79% vs 70%). Circadian rhythm was improved, while mean daytime and 24-hour BP reductions were comparable. Importantly, no increase in nocturnal hypotension was observed. These results support the use of bedtime dosing as a potential strategy for optimizing nocturnal blood pressure management in hypertension.
View ArticleEuropean Crohn’s and Colitis Organisation
What are the updated ECCO-ESGAR-ESP-IBUS recommendations for diagnosing and monitoring patients with inflammatory bowel disease?
Clinical Bottom Line: The 2025 ECCO-ESGAR-ESP-IBUS guideline recommends diagnosing IBD using a combination of clinical, endoscopic, histologic, and imaging assessments, with ileocolonoscopy plus intestinal ultrasound or MR enterography as first-line tests. For monitoring, endoscopy, imaging, and biomarkers should be used to assess disease activity, detect complications, and guide treatment decisions, with tailored approaches in pregnancy, postoperative care, and cancer surveillance.
Summary: This multi-society guideline updates the 2018 recommendations on the diagnostics and monitoring of Crohn’s disease and ulcerative colitis. It emphasizes colonoscopy with systematic biopsies as the cornerstone of diagnosis, complemented by intestinal ultrasound and MR enterography for small-bowel assessment. Histology remains essential for confirmation and grading of activity. For monitoring, the guideline highlights the roles of cross-sectional imaging, endoscopy, and histopathology, while also covering special contexts such as pregnancy, postoperative recurrence, and cancer surveillance. The document identifies key evidence gaps and calls for further research to refine diagnostic tools and improve patient-centered care.
View ArticleSociety of Obstetricians and Gynaecologists of Canada
How should primary dysmenorrhea be investigated and treated?
Clinical Bottom Line: Primary dysmenorrhea is common, often undertreated, and can significantly impair quality of life. First-line therapy includes NSAIDs and hormonal contraceptives, which can be initiated without pelvic examination. Non-pharmacological measures such as exercise, heat, TENS, and some complementary options may help. Pelvic imaging or laparoscopy is reserved for cases unresponsive to therapy or when secondary causes are suspected. Surgical options are last-line after optimized medical management.
Summary: The 2025 Canadian guideline on primary dysmenorrhea emphasizes prompt and effective treatment to prevent chronic pain and improve quality of life. NSAIDs and combined hormonal contraceptives remain first-line and are highly effective, while treatment should not be delayed pending definitive diagnosis. Ultrasound, MRI, or laparoscopy are considered only when symptoms persist despite therapy or secondary pathology (e.g., endometriosis) is suspected. Exercise, local heat, TENS, and selected complementary therapies may provide additional benefit. Surgery is reserved for refractory cases. The guideline encourages patient-centered care and early symptom control, given the low cost and high effectiveness of available treatments.
View ArticleTools for Practice
Can once-weekly insulin icodec replace daily long-acting insulin in type 2 diabetes?
Clinical Bottom Line: Once-weekly insulin icodec provides glycemic control comparable to daily glargine or degludec in type 2 diabetes, with similar hypoglycemia risk. It may improve convenience and adherence, but long-term safety data, especially in frail or high-risk patients, remain limited. Cost is higher than daily basal insulins.
Summary: Meta-analyses of randomized trials (~3700 patients, mean age 60, HbA1c 8.6%) show insulin icodec lowers HbA1c by about 1.45%, similar to daily basal insulins, with 49% vs 40% achieving HbA1c <7% (NNT = 11). Rates of clinically significant or severe hypoglycemia were low and similar between groups. Trials were largely open-label and industry-funded, and evidence is limited for older adults, sick-day management, and perioperative use. Once-weekly insulin could improve adherence, but at a higher cost and with unanswered questions about rare but severe hypoglycemia.
View Article
